What does the research say about Semaglutide?

Q: What does the research say about Semaglutide?

The scientific consensus on Semaglutide is unknown. No claims extracted for this topic Based on 0 analyzed claims.

Semaglutide — Research & Evidence

New research on Semaglutide

Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure

Biomolecules — Crispino S — Nov 2025

Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists

Cardiovascular Toxicology — Khatami S — Jul 2026

Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study

Frontiers in Endocrinology — Kahkedjian F — Jul 2026

Long-term effects of weight-reducing drugs in people with hypertension

Cochrane Database of Systematic Reviews — Spary-Kainz U — Jun 2026

Highlighting the latest research: May 2026

British Journal of Cardiac Nursing — McSharry S — May 2026

B52-20 A Broken Heart: Ozempic-Induced Takotsubo Cardiomyopathy

American Journal of Respiratory and Critical Care Medicine — Shah S — May 2026

Comparative 12-month cardiometabolic impact of semaglutide vs tirzepatide: a synthetic propensity-matched analysis

Cardiovascular Research — Fazio G — May 2026

Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study

Diabetes and Vascular Disease Research — Qadeer A — May 2026

Metabolic and nutritional stress-associated dilated cardiomyopathy in the setting of semaglutide use and long-term nicotine replacement therapy: a case report and literature review

Therapeutic Advances in Drug Safety — Sriram S — May 2026

Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5

Journal of Endocrinological Investigation — Galindo R — Apr 2026

Hemodynamic Changes in Response to GLP-1 Treatment in ICD and CRT Patients: Insights From HeartLogic Sensor Data

European Journal of Heart Failure — Fussing F — Apr 2026

Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly

Diabetes Care — Ganeshalingam A — Mar 2026

Evidence brief: Semaglutide

Semaglutide (also known as Semaglutide, Ozempic, Wegovy). Peer-reviewed research on semaglutide across obesity, type 2 diabetes, and cardiovascular outcome trials.

As of 2026-08-14, the scientific consensus on Semaglutide is unknown. No claims extracted for this topic

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/peptide-semaglutide.

Deterministic synthesis from Synapse's enriched corpus — 47 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

Semaglutide

What the evidence says about Semaglutide